Met Life Investment Management, LLC Arbutus Biopharma Corp Transaction History

Met Life Investment Management, LLC

  • $16.6 Billion
  • Q2 2024

A detailed history of Met Life Investment Management, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Met Life Investment Management, LLC holds 81,711 shares of ABUS stock, worth $306,416. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,711
Previous 61,872 32.06%
Holding current value
$306,416
Previous $159,000 58.49%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$2.52 - $3.63 $49,994 - $72,015
19,839 Added 32.06%
81,711 $252,000
Q1 2024

May 14, 2024
BUY
$2.26 - $2.92 $139,830 - $180,666
61,872 New
61,872 $159,000
Q2 2023

Apr 29, 2024
BUY
$2.24 - $3.06 $132,117 - $180,481
58,981 New
58,981 $135,000
Q1 2023

May 09, 2024
BUY
$2.23 - $3.1 $131,527 - $182,841
58,981 New
58,981 $179 Million
Q1 2023

May 15, 2023
BUY
$2.23 - $3.1 $33,106 - $46,022
14,846 Added 33.64%
58,981 $178,000
Q4 2022

May 10, 2024
SELL
$1.91 - $2.85 $27,353 - $40,814
-14,321 Reduced 24.5%
44,135 $102,000
Q4 2022

Jun 14, 2023
SELL
$1.91 - $2.85 $28,355 - $42,311
-14,846 Reduced 25.17%
44,135 $102,000
Q4 2022

Mar 22, 2023
SELL
$1.91 - $2.85 $27,353 - $40,814
-14,321 Reduced 24.5%
44,135 $102,000
Q4 2022

Feb 15, 2023
SELL
$1.91 - $2.85 $27,353 - $40,814
-14,321 Reduced 24.5%
44,135 $102,000
Q3 2022

May 10, 2024
BUY
$1.88 - $2.88 $43,826 - $67,138
23,312 Added 66.33%
58,456 $111,000
Q3 2022

Jun 14, 2023
SELL
$1.88 - $2.88 $987 - $1,512
-525 Reduced 0.89%
58,456 $111,000
Q3 2022

Mar 22, 2023
BUY
$1.88 - $2.88 $43,826 - $67,138
23,312 Added 66.33%
58,456 $111,000
Q3 2022

Nov 14, 2022
BUY
$1.88 - $2.88 $43,826 - $67,138
23,312 Added 66.33%
58,456 $112,000
Q2 2022

May 10, 2024
SELL
$1.98 - $3.17 $8,878 - $14,214
-4,484 Reduced 11.32%
35,144 $95,000
Q2 2022

Jun 20, 2023
SELL
$1.98 - $3.17 $47,197 - $75,563
-23,837 Reduced 40.41%
35,144 $95,000
Q2 2022

Mar 22, 2023
SELL
$1.98 - $3.17 $8,878 - $14,214
-4,484 Reduced 11.32%
35,144 $95,000
Q2 2022

Aug 11, 2022
SELL
$1.98 - $3.17 $8,878 - $14,214
-4,484 Reduced 11.32%
35,144 $95,000
Q1 2022

May 10, 2024
BUY
$2.42 - $3.98 $95,899 - $157,719
39,628 New
39,628 $118,000
Q1 2022

Jun 20, 2023
SELL
$2.42 - $3.98 $46,834 - $77,024
-19,353 Reduced 32.81%
39,628 $118,000
Q1 2022

Mar 22, 2023
BUY
$2.42 - $3.98 $71,748 - $117,999
29,648 Added 297.07%
39,628 $118,000
Q1 2022

May 12, 2022
BUY
$2.42 - $3.98 $71,748 - $117,999
29,648 Added 297.07%
39,628 $118,000
Q4 2021

May 17, 2024
SELL
$3.11 - $4.61 $62,392 - $92,485
-20,062 Reduced 66.78%
9,980 $38,000
Q4 2021

Jun 21, 2023
SELL
$3.11 - $4.61 $152,393 - $225,894
-49,001 Reduced 83.08%
9,980 $38,000
Q4 2021

Mar 22, 2023
SELL
$3.11 - $4.61 $62,392 - $92,485
-20,062 Reduced 66.78%
9,980 $38,000
Q4 2021

Feb 15, 2022
SELL
$3.11 - $4.61 $62,392 - $92,485
-20,062 Reduced 66.78%
9,980 $39,000
Q3 2021

May 17, 2024
SELL
$2.65 - $4.62 $84,349 - $147,054
-31,830 Reduced 51.44%
30,042 $128,000
Q3 2021

Jun 21, 2023
SELL
$2.65 - $4.62 $76,688 - $133,698
-28,939 Reduced 49.06%
30,042 $128,000
Q3 2021

Mar 22, 2023
BUY
$2.65 - $4.62 $3,908 - $6,814
1,475 Added 5.16%
30,042 $128,000
Q3 2021

Nov 15, 2021
BUY
$2.65 - $4.62 $79,611 - $138,794
30,042 New
30,042 $129,000
Q4 2018

Feb 14, 2019
SELL
$3.5 - $9.66 $99,984 - $275,957
-28,567 Closed
0 $0
Q3 2018

Jul 13, 2023
SELL
$7.85 - $12.35 $317,163 - $498,977
-40,403 Reduced 68.5%
18,578 $175,000
Q3 2018

Mar 22, 2023
SELL
$7.85 - $12.35 $122,208 - $192,264
-15,568 Reduced 35.27%
28,567 $269,000
Q3 2018

Nov 14, 2018
BUY
$7.85 - $12.35 $224,250 - $352,802
28,567 New
28,567 $270,000

Others Institutions Holding ABUS

# of Institutions
141
Shares Held
95.7M
Call Options Held
3.44M
Put Options Held
377K
View Full List

About Arbutus Biopharma Corp

ABUS Quotes by TradingView
  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $562M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email